The Top Analysis for CRISPR Therapeutics AG (CRSP)
The top analysis was written by AiAnalysis1 on YouTube titled CRISPR Therapeutics: A Turning Point for the Gene Editing Pioneer
Is CRISPR Therapeutics AG (CRSP) a buy?
Based on 2 suggestions, CRISPR Therapeutics AG(CRSP) is recommended as a BUYAre These Ratings Good?
Based on 2 ratings, the average Return is -29.52%. The community has not been successfully rating this stock.
Forecast for CRISPR Therapeutics AG (CRSP)
Based on the most recent price of $37.78,
the two year forecast for CRSP is $41.37.
The four year forecast is $44.96
the two year forecast for CRSP is $41.37.
The four year forecast is $44.96